Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway

被引:81
作者
Chapman, E. J.
Hurst, C. D.
Pitt, E.
Chambers, P.
Aveyard, J. S.
Knowles, M. A.
机构
[1] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England
[2] St James Univ Hosp, Canc Res UK Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England
关键词
urothelial; immortalisation; telomerase; p16; p53;
D O I
10.1038/sj.onc.1209513
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The CDKN2A locus is frequently inactivated in urothelial cell carcinoma (UCC), yet how this alteration contributes to bladder tumorigenesis is not known. Although most UCC express telomerase, inactivation of the p16/Rb pathway is generally required for in vitro immortalisation. This and the involvement of p16 in senescence of normal human urothelial cells (NHUC) suggest that CDKN2A deletion may aid bypass of senescence and allow immortalisation. CDKN2A encodes p16 and p14(ARF) and therefore inactivation of this locus can disrupt both the Rb and p53 tumour suppressor pathways. Retrovirus-mediated transduction was used to specifically modulate the p16/Rband/or p53 tumour suppressor pathways in NHUC and to express human telomerase reverse transcriptase (hTERT). Expression of hTERT bypassed Rb and p53 pathway-dependent barriers to proliferation and immortalised NHUC. TERT-NHUC had normal karyotypes, were non-tumorigenic and unexpectedly retained CDKN2A. Thus, the phenotypic significance of inactivation of CDKN2A in UCC may not be solely related to bypass of senescence. Phenotypic assays in human urothelial cells have relied on cell strains derived from invasive tumours or NHUC immortalised by expression of SV40-large T. The production of genetically normal but immortal NHUC lines now provides a valuable platform for experiments to examine the timing and combination of events necessary for UCC tumorigenesis.
引用
收藏
页码:5037 / 5045
页数:9
相关论文
共 47 条
[1]   Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a [J].
Alani, RM ;
Young, AZ ;
Shifflett, CB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (14) :7812-7816
[2]   Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts [J].
Alcorta, DA ;
Xiong, Y ;
Phelps, D ;
Hannon, G ;
Beach, D ;
Barrett, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) :13742-13747
[3]   Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification [J].
Aveyard, JS ;
Knowles, MA .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2004, 6 (04) :356-365
[4]   Telomerase activity: A biomarker of cell proliferation, not malignant transformation [J].
Belair, CD ;
Yeager, TR ;
Lopez, PM ;
Reznikoff, CA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :13677-13682
[5]   Extension of life-span by introduction of telomerase into normal human cells [J].
Bodnar, AG ;
Ouellette, M ;
Frolkis, M ;
Holt, SE ;
Chiu, CP ;
Morin, GB ;
Harley, CB ;
Shay, JW ;
Lichtsteiner, S ;
Wright, WE .
SCIENCE, 1998, 279 (5349) :349-352
[6]   Direct evidence from siRNA-directed "knock down" that p16INK4a is required for human fibroblast senescence and for limiting ras-induced epithelial cell proliferation [J].
Bond, J ;
Jones, C ;
Haughton, M ;
DeMicco, C ;
Kipling, D ;
Wynford-Thomas, D .
EXPERIMENTAL CELL RESEARCH, 2004, 292 (01) :151-156
[7]  
Bond JA, 1999, MOL CELL BIOL, V19, P3103
[8]   Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype [J].
Chapman, EJ ;
Harnden, P ;
Chambers, P ;
Johnston, C ;
Knowles, MA .
CLINICAL CANCER RESEARCH, 2005, 11 (16) :5740-5747
[9]  
Cote RJ, 1998, CANCER RES, V58, P1090
[10]   Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase [J].
Counter, CM ;
Meyerson, M ;
Eaton, EN ;
Ellisen, LW ;
Caddle, SD ;
Haber, DA ;
Weinberg, RA .
ONCOGENE, 1998, 16 (09) :1217-1222